ASB2 and acute myeloid leukemia: In terms of anti-tumor, compound 32 inhibited AML cell proliferation (IC50 = 1.6 ~ 16 μM), induce apoptosis and upregulate ASB2 and RARA, direct targets of FTO, to exert anti-tumor effects.